

**MARCH 2026 PBAC MEETING – CONSIDERATION OF THE REPORT OF THE  
DRUG UTILISATION SUB-COMMITTEE**

**PBAC CONSIDERATION OF THE REPORT OF THE  
DRUG UTILISATION SUB-COMMITTEE**

The PBAC noted reports with associated stakeholder responses from the February 2026 Drug Utilisation Sub-Committee (DUSC) meeting, which were provided in items 10.03, and 10.04 of the PBAC Agenda. DUSC minutes relating to these items were provided to the PBAC. The outcomes of the DUSC consideration of these items are available in the [February 2026 DUSC outcome statement](#).

**FLUTICASONE PROPIONATE FOR SEVERE ASTHMA**

*Outcome*

The PBAC noted that the drop in utilisation of fluticasone propionate 50 mcg in the eligible patient population has largely returned to pre-restriction change levels. The PBAC agreed that further restriction changes at this time were not warranted.

**MEPOLIZUMAB FOR CHRONIC RHINOSINUSITIS**

*Outcome*

The PBAC noted that the use of mepolizumab for chronic rhinosinusitis with nasal polyps was different than expected. The PBAC commented that the decrease in MBS services did appear promising but agreed with DUSC that the sudden decrease in services suggested the change was due to administrative changes to MBS item codes rather than the PBS listing of mepolizumab.